Biohaven Pharmaceuticals

Graphic image of a red thumbs down against a blue background
Biotech

FDA rejects Biohaven approval request, triggering cost cutting

Biohaven responded to the rejection of its neurological disorder therapy by reprioritizing its pipeline to shrink its annual R&D spend by 60%.
Nick Paul Taylor Nov 5, 2025 4:02am
Garbage truck picking up trash on suburban street

Biohaven trashes troriluzole in OCD after ph. 3 fail

Aug 12, 2025 2:06pm
delay FDA delay

FDA delays decision on Biohaven troriluzole filing, plans adcomm

May 15, 2025 6:02am
brain money funding

Biohaven lands funding Oberland funding deal worth up to $600M

Apr 28, 2025 4:43pm
long shot miss basketball hoop fail shoot

Biohaven's biopolar med fails pivotal test

Mar 3, 2025 5:14pm
plan B fail reroute road path trail miss

Biohaven fails phase 3 SMA test but plans talks with FDA

Nov 25, 2024 9:56am